Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX) from its SEC filings: 2025 revenue $46.0 million (-89% vs the year before), net margin -283%, free cash flow $56.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $46.0 million |
| Revenue growth | -89% |
| Net income | -$130.1 million |
| Net margin | -282.8% |
| Free cash flow | $56.1 million |
| Diluted EPS | $-2.05 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +3749% |
| Cash | $420.1 million |
| Long-term debt | $9.8 million |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.